Aster DM Healthcare Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026.
ASTERDM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Aster DM Healthcare's Board approved the audited Q4 and FY26 results on April 30, 2026, with auditor Deloitte Haskins & Sells giving a clean (unmodified) opinion. Standalone revenue from operations rose to INR 2,615.70 crores in FY26 from INR 2,320.48 crores in FY25, a growth of roughly 12.7%; Q4 FY26 revenue came in at INR 655.10 crores versus INR 573.86 crores in Q4 FY25. Standalone FY26 profit stood at INR 267.82 crores compared with INR 6,208.97 crores in FY25, with the prior year boosted by a one-time INR 5,569.96 crores dividend from the sale of the GCC business completed in April 2024. The company reported net exceptional items of INR 89.92 crores, including a INR 57.24 crores write-down on investments in a subsidiary and associate and INR 16.82 crores of one-time merger and acquisition advisory costs, partly offset by a INR 25.41 crores reversal of an old Kerala minimum-wages provision. The Board also declared an interim dividend of INR 3 per share, and the proposed merger with Quality Care India Limited received NCLT-convened shareholder and creditor approvals in March 2026. Operating cash flow remained healthy at INR 387.13 crores.
The clean audit opinion and steady revenue growth are reassuring, while headline FY profit looks sharply lower only because FY25 was inflated by a one-off dividend from the GCC divestment, not because the core India business deteriorated. Exceptional charges related to the QCIL merger and investment write-downs are near-term drags, but the merger itself, if completed, could meaningfully scale the India business.